Home LiteratureArticle Details
PMID: 3262710 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

The Journal of experimental medicine ·Vol. 168 ·No. 4 ·1988-10-01 ·Pages 1419-41

Itoh K, Platsoucas CD, Balch CM

Abstract

TIL from metastatic melanoma proliferated by greater than 1,000-fold (840-3,675, mean 1,543) after 6 wk in culture of mixtures of TIL and tumor cells with rIL-2 alone. Cytolysis was restricted to autologous tumor cells. CD8+ T cells were the predominant population of TIL before and after expansion, and were primarily responsible for autologous tumor-specific CTL activity. No other rIL-2-activated lymphocytes from peripheral blood, lymph nodes with melanoma metastasis, or TIL from sarcoma or renal cell carcinoma had autologous tumor-specific CTL activity. There were few or no CD16+ NK cells in TIL from metastatic melanoma before or after incubation with rIL-2, respectively. However, TIL from sarcoma or renal cell carcinoma contained a substantial proportion of CD3-CD16+ NK cells, which increased in number in culture with rIL-2. Purified CD16+ NK cells as well as CD3+CD16- T cells from rIL-2-activated TIL of renal cell carcinoma displayed MHC-nonrestricted cytotoxicity. At the clonal level as determined by limiting dilution, 8 of 10 clones from melanoma TIL displayed cytotoxicity restricted to autologous tumor cells, while all 13 clones from renal cancer TIL equally lysed autologous and allogeneic tumor cells. Anti-T cell receptor (TCR)-alpha/beta(WT31) mAb as well as anti-CD3 mAb inhibited autologous melanoma cell-specific CTL activity mediated by rIL-2-activated TIL at the effector phase. These two mAbs also inhibited rIL-2-dependent proliferation of these TIL when added to the culture. Pretreatment of fresh melanoma cells with mAb to MHC antigens followed by washing inhibited specific CTL activity. These results suggest that both TCR-alpha/beta on effector TIL and MHC antigens on fresh tumor cells are involved in the specific immune-recognition. After reaching maximum propagation, TIL from metastatic melanoma responded poorly to rIL-2 alone. However, stimulation with fresh autologous melanoma cells restored both CTL activity and proliferation in response to rIL-2. The latter is associated with IL-2 receptor (Tac antigen) expression on the surface. These results indicate that TIL from metastatic melanomas may have unique characteristics different from lymphocytes obtained from the other sources, and may contain precursor CTL sensitized in vivo to autologous tumor cells, and thus can be propagated in larger numbers with rIL-2 alone while retaining autologous tumor-specific CTL activity.

MeSH Terms
Antibodies, Monoclonal/immunology Cells, Cultured Clone Cells Cytotoxicity, Immunologic Humans Interleukin-2/immunology Kinetics Lymphocyte Activation Major Histocompatibility Complex Melanoma/immunology Receptors, Antigen, T-Cell/immunology Recombinant Proteins/immunology T-Lymphocytes, Cytotoxic/immunology
Chemicals
Antibodies, Monoclonal Interleukin-2 Receptors, Antigen, T-Cell Recombinant Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Itoh K
Department of General Surgery, University of Texas, M. D. Anderson Cancer Center, Houston 77030.
Platsoucas C D
Balch C M
References (35)
35 references, click to expand
  1. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Cancer Res. 1988 Jan 1;48(1):206-14 PMID: 3257161
  2. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Cancer Res. 1987 Dec 1;47(23):6353-62 PMID: 3315186
  3. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.
    J Immunol. 1980 Oct;125(4):1487-93 PMID: 6967906
  4. Inhibition of specific cell-mediated cytotoxicity by monoclonal antibodies to human T cell antigens.
    Proc Natl Acad Sci U S A. 1981 Jul;78(7):4500-4 PMID: 6974866
  5. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.
    J Exp Med. 1982 Apr 1;155(4):1133-47 PMID: 7061953
  6. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    J Exp Med. 1982 Jun 1;155(6):1823-41 PMID: 6176669
  7. Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity.
    J Exp Med. 1983 Feb 1;157(2):743-54 PMID: 6600491
  8. Clonal analysis of cytotoxic T cell response against human melanoma.
    J Exp Med. 1983 Jul 1;158(1):240-5 PMID: 6602860
  9. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
    J Immunol. 1984 Jan;132(1):510-9 PMID: 6197458
  10. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.
    Proc Natl Acad Sci U S A. 1984 Jun;81(11):3511-5 PMID: 6610177
  11. Human T cell antigens involved in cytotoxicity against allogeneic or autologous chemically modified targets. Association of the Leu 2a/T8 antigen with effector-target cell binding and of the T3/Leu 4 antigen with triggering.
    Eur J Immunol. 1984 Jun;14(6):566-77 PMID: 6610558
  12. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
    J Immunol. 1985 Feb;134(2):802-7 PMID: 3917475
  13. Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma.
    Int J Cancer. 1985 May 15;35(5):683-9 PMID: 3158614
  14. Lysis of anti-T3-bearing murine hybridoma cells by human allospecific cytotoxic T cell clones and inhibition of that lysis by anti-T3 and anti-LFA-1 antibodies.
    J Immunol. 1985 Jul;135(1):5-8 PMID: 2582047
  15. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells.
    Cancer Res. 1985 Jul;45(7):3173-8 PMID: 3924397
  16. Characteristics of a monoclonal antibody (WT-31) that recognizes a common epitope on the human T cell receptor for antigen.
    J Immunol. 1985 Sep;135(3):1922-8 PMID: 2410507
  17. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    J Immunol. 1986 May 15;136(10):3910-5 PMID: 3084648
  18. Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.
    Cancer Immunol Immunother. 1986;22(1):15-23 PMID: 2423240
  19. Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.
    J Immunol. 1986 Jul 15;137(2):502-11 PMID: 2424971
  20. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.
    J Exp Med. 1986 Sep 1;164(3):814-25 PMID: 3489062
  21. Lymphokine-activated killer cells. Analysis of progenitors and effectors.
    J Exp Med. 1986 Oct 1;164(4):1193-205 PMID: 3093626
  22. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes.
    Cancer Res. 1987 Jan 1;47(1):173-7 PMID: 3491673
  23. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.
    Proc Natl Acad Sci U S A. 1986 Dec;83(24):9694-8 PMID: 3099289
  24. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.
    J Immunol. 1987 Feb 1;138(3):989-95 PMID: 3100623
  25. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    J Immunol. 1987 Feb 15;138(4):1068-73 PMID: 3100627
  26. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
    J Immunol. 1987 Feb 15;138(4):1297-302 PMID: 3100633
  27. Natural killer cells in the host response to melanoma.
    Cancer Res. 1987 Mar 1;47(5):1411-2 PMID: 3815344
  28. Production of stable cytolytic T-cell clones directed against autologous human melanoma.
    Int J Cancer. 1987 Mar 15;39(3):390-6 PMID: 3493226
  29. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis.
    J Immunol. 1987 Mar 15;138(6):1779-85 PMID: 3493287
  30. In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.
    J Natl Cancer Inst. 1987 Mar;78(3):441-50 PMID: 3102826
  31. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
    N Engl J Med. 1987 Apr 9;316(15):889-97 PMID: 3493432
  32. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    N Engl J Med. 1987 Apr 9;316(15):898-905 PMID: 3493433
  33. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
    J Immunol. 1987 Apr 15;138(8):2728-33 PMID: 2435804
  34. Lysis of fresh solid tumor targets in the presence of Con A is mediated primarily by Leu 7+ peripheral blood T lymphocytes: blocking by the anti-CD3 monoclonal antibody and comparison with recombinant interleukin 2-induced lysis by natural killer cells.
    Cell Immunol. 1987 Sep;108(2):283-96 PMID: 3113741
  35. Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms.
    Proc Natl Acad Sci U S A. 1980 Apr;77(4):2183-7 PMID: 6929544
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1988-10-01
Pages
1419-41
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2189080
Subset
IM
Grants
NCI NIH HHS · CA-41699 · United States
NCRR NIH HHS · RR-5511-25 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]